|This article needs additional citations for verification. (December 2009)|
|Systematic (IUPAC) name|
|Molar mass||302.451 g/mol|
Norethandrolone (INN, BAN) (brand names Nilevar, Pronabol), also known as 17α-ethyl-19-nortestosterone, is an anabolic steroid. It was synthesized at G. D. Searle & Company in 1953 and was originally studied as a progestin, along with norethisterone and noretynodrel, but was ultimately not marketed as such. In 1955, it was re-examined for testosterone-like activity and was found to have similar anabolic activity to testosterone but only one-sixteenth the androgenic potency. The drug was introduced in the United States as an anabolic steroid in 1965 under the trade name Nilevar but was withdrawn from the market in the 1980s due to concerns of cholestatic jaundice. Norethandrolone is now only marketed in Australia, France, and Switzerland, and as with all 17α-alkylated oral steroids, long-term use in high doses may result in elevated liver enzymes and consequently cirrhosis. It is used in the treatment of muscle wasting, patients with severe burns, after severe trauma, and for certain forms of aplastic anemia.
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 885–. ISBN 978-1-4757-2085-3.
- Nicolae Sfetcu (2 May 2014). Health & Drugs: Disease, Prescription & Medication. Nicolae Sfetcu. pp. 1051–. GGKEY:JPFE1Q59083.
- Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 380–. ISBN 978-3-642-66353-6.
- Walter Sneader (23 June 2005). Drug Discovery: A History. John Wiley & Sons. pp. 206–. ISBN 978-0-471-89979-2.
- W., Llewellyn. (2005). Anabolics. p. 156.
- D., Lednicer. (2011). Steroid Chemistry at Glance. Wiley. p. 67.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|